Myeloma cells can disrupt the interplay between RANKL and its soluble decoy receptor osteoprotegerin (OPG) by increasing the RANKL and decreasing the OPG expressions and promoting the formation and activation of osteoclasts [15]. The gene discussed is TNFRSF11B; the disease is plasma cell myeloma.